Is CJC-1295 Legal in Washington State? What Women Need to Know

What Is CJC-1295 and Why Are Women Asking About It?

CJC-1295 is a synthetic analog of growth-hormone-releasing hormone (GHRH). It binds to GHRH receptors in the pituitary and stimulates the release of endogenous growth hormone (GH) in pulses. The version most commonly prescribed in clinical practice is CJC-1295 without DAC (drug affinity complex), which has a short half-life of roughly 30 minutes, mimicking the body's natural pulsatile GH release pattern. The version with DAC extends that half-life to approximately 6 to 8 days by binding covalently to albumin.

Women are asking about CJC-1295 for reasons that are deeply tied to female physiology. GH secretion declines with age in both sexes, but women experience a sharper decline during perimenopause and after menopause, a period when estrogen, which normally amplifies GH pulses, drops dramatically. Research published in the Journal of Clinical Endocrinology and Metabolism documented that GH pulse amplitude in women is approximately twice that of age-matched men during reproductive years, meaning the relative loss of GH secretion during menopause is proportionally larger. Women are also disproportionately affected by the metabolic consequences of GH deficiency: increased visceral fat, reduced lean mass, disrupted sleep architecture, and fatigue. These symptoms overlap precisely with perimenopause, which is why interest in GHRH analogs has grown among women in their 40s and 50s.

This article focuses specifically on Washington State because state pharmacy law and medical-practice rules shape what your prescriber can legally do, even within the federal framework.

The Federal Regulatory Framework: Where CJC-1295 Sits Right Now

CJC-1295 is not an FDA-approved drug. Understanding what that means in practice requires looking at two federal layers: drug-approval law and compounding pharmacy law.

FDA Approval Status

No new drug application (NDA) or biologics license application (BLA) has been approved by the FDA for CJC-1295 in any indication. The FDA drug database returns no approved product for CJC-1295. This means it cannot be marketed, advertised, or sold as a finished pharmaceutical product in the United States.

Because CJC-1295 is not approved, it also cannot legally be sold as a dietary supplement, despite what some online retailers claim. The FDA's position is that peptides with pharmacological action that are not on the approved supplement ingredient list are unapproved drugs, not supplements.

The Compounding Exemption: 503A and 503B Pharmacies

Federal law, specifically the Drug Quality and Security Act of 2013, created two compounding tracks that allow licensed pharmacies to prepare unapproved substances under certain conditions. Section 503A covers traditional compounding pharmacies that prepare individualized prescriptions for identified patients. Section 503B covers outsourcing facilities that can produce larger batches without patient-specific prescriptions, primarily for hospitals and clinics.

For a substance to be compounded under 503A, it must appear on the FDA's list of bulk drug substances that can be used in compounding, or it must meet other specific criteria. This is where CJC-1295's legal status becomes genuinely uncertain.

The Bulk Drugs List Problem

The FDA maintains a list of bulk drug substances that are permissible for 503A compounding (the so-called "positive list" or Category 1 list). As of January 2025, CJC-1295 does not appear on the FDA 503A positive bulk drug list. The FDA has also proposed, and in some cases finalized, rules that restrict compounding of substances that appear on its "Difficult to Compound" or category 2 lists. Many GHRH analogs, including sermorelin (a shorter GHRH fragment), have received clearer regulatory treatment than CJC-1295.

Sermorelin, by contrast, is compoundable and has a more established regulatory pathway. CJC-1295 occupies a grayer space: it is not explicitly prohibited by name on a negative list, but its absence from the 503A positive list means a 503A pharmacy technically lacks clear federal authorization to compound it for patient-specific prescriptions.

The practical consequence is that some compounding pharmacies do compound CJC-1295 today, operating under legal interpretations that the substance has not been explicitly banned. Others refuse, judging the regulatory uncertainty too high. The FDA has not issued a specific enforcement action naming CJC-1295 as of this writing, but the agency has been increasing scrutiny of peptide compounding broadly. The FDA's 2023 guidance on bulk peptide compounding signaled closer oversight of this category.

This is a genuine gray area. Calling it legal without qualification would be inaccurate. Calling it explicitly illegal under Washington state law would also be inaccurate because no Washington statute specifically names CJC-1295. What is accurate is this: the federal compounding framework does not clearly authorize it, and no Washington-specific law adds clarity.

Washington State Law: What the State Pharmacy Board and Medical Practice Act Say

Washington State does not have a separate statute that independently legalizes or bans CJC-1295. Instead, Washington pharmacy and prescribing law layers on top of federal rules.

Washington State Pharmacy Board

The Washington State Pharmacy Quality Assurance Commission (PQAC) regulates compounding pharmacies operating in the state. Washington pharmacies must comply with United States Pharmacopeia (USP) standards (USP 795 for non-sterile and USP 797 for sterile compounding) and must follow federal law on bulk drug substances. Because PQAC does not maintain a separate state-level positive list for bulk drug substances, the practical question is always: does the substance comply with federal compounding law? For CJC-1295, as explained above, that compliance is uncertain.

A Washington-licensed 503A pharmacy that compounds CJC-1295 is making a legal judgment call. It is not automatically acting in violation of Washington state law by doing so, because Washington has not independently prohibited it. But it is operating in federal regulatory gray space.

Washington Medical Practice Act and Prescribing Authority

Under the Washington Medical Practice Act (RCW 18.71), licensed physicians may prescribe substances for legitimate medical purposes. Washington also grants prescribing authority to advanced registered nurse practitioners (ARNPs) under RCW 18.79 and to physician assistants under RCW 18.71A. A prescriber writing for compounded CJC-1295 must be doing so for a legitimate, individualized patient need, with documentation supporting that clinical decision.

Off-label prescribing of compounded substances is legal in Washington, as in all U.S. States, provided the prescriber exercises sound clinical judgment and the compounding pharmacy meets applicable standards. The risk to the prescriber is not state-law prosecution for prescribing CJC-1295 specifically, but rather potential board scrutiny if prescribing is done without adequate clinical evaluation, documentation, or follow-up.

Telehealth Prescribing in Washington

Washington's telehealth parity law (RCW 48.43.735) allows licensed Washington clinicians to prescribe through telehealth platforms, including for compounded medications, provided the prescriber-patient relationship is established appropriately. For a women's telehealth platform like WomanRx, this means a Washington-licensed NP or MD can evaluate you, order appropriate labs, and issue a prescription for a compounding pharmacy, all without an in-person visit, as long as the clinical standards are met.

How Women Actually Access CJC-1295 in Washington

Getting CJC-1295 legally in Washington requires moving through four distinct steps, each with its own gatekeeping function.

Step 1: A Clinical Evaluation with a Licensed Washington Prescriber

This is not optional formality. A prescriber needs to document why CJC-1295 is clinically appropriate for you specifically. For women, that evaluation should include at minimum: fasting IGF-1 (insulin-like growth factor 1, the primary surrogate marker for GH status), fasting glucose and insulin, a thyroid panel (because GH and thyroid function interact closely), and a review of your current hormonal status, including estradiol, FSH, and, if relevant, progesterone. Sleep quality, body composition, menstrual history, and symptoms of GH deficiency (fatigue, increased visceral fat, poor recovery, cognitive fog) should be documented.

Skipping this step and purchasing CJC-1295 from an online "research chemical" supplier is purchasing an unregulated, untested substance with no quality controls. That is a different category of legal and safety risk entirely.

Step 2: A Patient-Specific Prescription

Your prescriber issues a written, patient-specific prescription. This cannot be a standing order for a population of patients. Under 503A rules, compounding must be for an identified individual based on a practitioner-patient relationship and a legitimate medical need.

Step 3: A Licensed Compounding Pharmacy That Agrees to Compound CJC-1295

Not every compounding pharmacy in Washington will prepare CJC-1295. You or your prescriber will need to identify a PQAC-licensed pharmacy that compounds it, accepts the legal interpretation that it is permissible under current federal rules, and meets USP 797 sterile-compounding standards (CJC-1295 is administered by subcutaneous injection, making sterility critical).

Step 4: Ongoing Monitoring

A responsible prescriber does not write the prescription and disappear. IGF-1 should be re-checked 8 to 12 weeks after starting therapy, and labs should be reviewed against the age- and sex-specific reference ranges. For women, those ranges differ by menopausal status, and interpreting IGF-1 in the context of concurrent hormone therapy is important because estrogen suppresses IGF-1 levels, meaning a woman on oral estrogen may have an artificially lower IGF-1 despite adequate GH secretion.

Sex-Specific Physiology: How CJC-1295 Works Differently in Women

The data on CJC-1295 in women specifically are thin. Most of the foundational human research used mixed-sex populations with small female subgroups, or enrolled exclusively men. A 2006 RCT by Teichman et al. In JCEM evaluated CJC-1295 (with DAC) in healthy adults aged 21 to 61 and showed dose-dependent increases in GH and IGF-1, but the trial enrolled more men than women and did not report sex-stratified outcomes. This is a meaningful evidence gap, and you deserve to know it exists.

What we do know from broader GH physiology research:

Estrogen and GH Sensitivity

Estrogen, specifically estradiol, increases pituitary sensitivity to GHRH. During the reproductive years, this means your GH pulse amplitude is naturally higher than a man's of the same age. After menopause, without estrogen, pituitary GHRH sensitivity drops. A GHRH analog like CJC-1295 may produce a different IGF-1 response in a postmenopausal woman than in a premenopausal woman, and concurrent hormone therapy (HRT) may modify that response further.

Route of Estrogen Administration Matters

Research in the Journal of Clinical Endocrinology and Metabolism showed that oral estrogen suppresses hepatic IGF-1 production while transdermal estrogen does not, because oral estrogen creates a hepatic first-pass effect that blunts GH signaling. If you are on oral estrogen and your prescriber is dosing CJC-1295 based on IGF-1 levels alone, your labs may underestimate your true GH status. Transdermal estrogen does not create this artifact.

Menstrual Cycle Phase Effects

In premenopausal women, GH secretion naturally peaks in the luteal phase and around ovulation. Exogenous GHRH stimulation layered on top of this may produce variable IGF-1 responses depending on cycle phase. No clinical trial has mapped CJC-1295 dosing to menstrual cycle phase in women. This is another gap to acknowledge honestly.

PCOS Considerations

Women with polycystic ovary syndrome (PCOS) often have dysregulated GH-IGF-1 axis signaling. Studies published in Fertility and Sterility have noted that insulin resistance in PCOS can impair hepatic IGF-1 generation independently of GH secretion. Introducing a GHRH analog in this context requires careful interpretation of IGF-1 labs, and the interaction with insulin-sensitizing agents like metformin has not been studied for CJC-1295 specifically.

Pregnancy, Lactation, and Contraception: A Required Section

CJC-1295 should not be used during pregnancy. There are no human safety data for CJC-1295 in pregnancy. No animal reproductive toxicology studies sufficient to assess teratogenicity have been published in peer-reviewed literature for this specific compound. Because GH excess during pregnancy carries known risks, including gestational diabetes and macrosomia, stimulating GH release with an exogenous GHRH analog during pregnancy is not clinically justifiable given the absence of safety data.

The FDA's framework for unapproved drugs in pregnancy assigns CJC-1295 no formal pregnancy category because it is not approved, but the principle of precautionary avoidance applies directly.

During lactation: GH is present in breast milk in small amounts, but whether exogenously stimulated GH elevations or CJC-1295 itself transfers into breast milk is unknown. No lactation safety data exist. Women who are breastfeeding should not use CJC-1295.

Contraception requirement: If you are of reproductive age and considering CJC-1295, your prescriber should confirm you are using reliable contraception or are not sexually active, and that a pregnancy test is negative before initiating therapy. This is not a legal requirement specific to CJC-1295 the way it is for teratogenic drugs like isotretinoin, but it is sound clinical practice given the complete absence of pregnancy safety data.

Trying to conceive: CJC-1295 should be discontinued before attempting conception. Some clinicians discuss whether GHRH analogs might theoretically support oocyte quality or implantation through IGF-1 signaling, but there is no clinical trial evidence supporting use of CJC-1295 for fertility in women, and the risk-benefit calculation does not support it outside of a controlled research setting.

Who This May Be Right For, and Who It Is Not

This is not a supplement for everyone who feels tired. The clinical profile of a woman who might be an appropriate candidate for CJC-1295 evaluation in Washington looks like this:

• Documented low or low-normal IGF-1 for age and menopausal status, confirmed on fasting labs
• Symptoms consistent with GH insufficiency (not frank GH deficiency, which is a pituitary disease): fatigue, increased central adiposity despite adequate diet and exercise, poor sleep, slow recovery from training
• Postmenopausal or perimenopausal, with symptoms not fully addressed by hormone therapy
• No active malignancy or personal history of hormone-sensitive cancer (GH stimulation is contraindicated with active malignancy per Endocrine Society guidelines on GH therapy)
• No uncontrolled diabetes (GH raises blood glucose; CJC-1295 can worsen insulin resistance at higher IGF-1 levels)
• Not pregnant, not breastfeeding, using reliable contraception if premenopausal

CJC-1295 is likely not appropriate for you if you have a history of breast cancer, ovarian cancer, or endometrial cancer. The relationship between IGF-1 and breast cancer risk has been studied in prospective data: the Nurses' Health Study found higher circulating IGF-1 associated with increased premenopausal breast cancer risk. This does not prove CJC-1295 causes breast cancer, but it argues for caution and oncologist consultation before use in any woman with a relevant history.

Women with active thyroid disease should have their thyroid optimized before starting any GH-axis intervention, since GH and thyroid hormone metabolism are tightly linked and changes in GH secretion may alter T4-to-T3 conversion.

What "Research Chemical" Suppliers Are and Why They Are Not the Same Thing

Searching online for CJC-1295 in Washington will return dozens of websites selling it as a "research chemical" for "laboratory use only." These suppliers operate on the legal theory that selling a compound labeled "not for human use" sidesteps FDA drug-approval requirements. In practice, these products:

• Are not manufactured under current Good Manufacturing Practice (cGMP) standards
• Have no quality control documentation you can verify
• May contain incorrect doses, impurities, or microbial contamination
• Are not legal for human use regardless of the label

Purchasing CJC-1295 from a research-chemical supplier for self-injection is not the same as receiving compounded CJC-1295 from a licensed 503A pharmacy under a physician's prescription. The legal exposure, the safety risk, and the clinical accountability are entirely different. Washington's consumer protection statutes do not offer meaningful recourse if you are harmed by an unregulated compound you purchased for self-administration.

The Bottom Line on Legal Access in Washington

Washington state does not have a law that explicitly legalizes or bans CJC-1295. The real legal constraint is federal: CJC-1295 is not on the FDA 503A positive bulk-drug list, creating genuine regulatory uncertainty for compounding pharmacies. Some licensed Washington compounding pharmacies do prepare it under a legal interpretation that it is not explicitly prohibited. A licensed Washington prescriber can write for it if there is a legitimate, documented clinical need.

The pathway that is both legally defensible and clinically sound is: evaluation by a Washington-licensed clinician with appropriate lab work, a patient-specific prescription, dispensing by a licensed compounding pharmacy meeting USP 797 sterile-compounding standards, and ongoing monitoring of IGF-1 and metabolic labs.

If a website, clinic, or online seller tells you CJC-1295 is "fully legal" in Washington without any of these qualifications, that is an oversimplification of a genuinely complex regulatory picture.

Your next step, if you are curious whether CJC-1295 is appropriate for you, is to schedule a consultation with a Washington-licensed women's health clinician, bring your most recent fasting labs, and have a frank conversation about your goals, your hormonal status, and whether the evidence supports this intervention for your specific situation. IGF-1 reference ranges for women aged 40 to 60 on the Mayo Clinic reference intervals typically fall between 94 and 252 ng/mL depending on age bracket, and your number in context matters more than any single data point.